Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib Open-Label Extension Study
NCT03744715Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Oct 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), breast cancer, sponsored by Spectrum Pharmaceuticals, Inc.. Started Oct 2018; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT03744715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744715.